New hope for hard-to-treat colon cancer: drug combo targets resistant tumors
NCT ID NCT05990543
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tests a new combination of two drugs, nelmastobart and capecitabine, in people with advanced colorectal cancer that has stopped responding to or cannot tolerate standard chemotherapies. The goal is to see if this combination is safe and can help control the cancer or shrink tumors. About 59 adults with recurrent or metastatic colorectal cancer are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Korea University Medical Center 73, Goryeodae-ro, Seongbuk-gu
Seoul, Seoul, 02841, South Korea
Conditions
Explore the condition pages connected to this study.